The Manufacturers Life Insurance Company Buys Shares of 31,309 LENZ Therapeutics, Inc. (NASDAQ:LENZ)

The Manufacturers Life Insurance Company bought a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) during the third quarter, HoldingsChannel reports. The institutional investor bought 31,309 shares of the company’s stock, valued at approximately $743,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of LENZ Therapeutics in the third quarter valued at approximately $107,000. GSA Capital Partners LLP bought a new stake in shares of LENZ Therapeutics in the third quarter valued at approximately $246,000. Squarepoint Ops LLC bought a new stake in shares of LENZ Therapeutics in the second quarter valued at approximately $181,000. Rhumbline Advisers raised its position in shares of LENZ Therapeutics by 265.6% in the second quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock valued at $291,000 after purchasing an additional 12,214 shares during the period. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of LENZ Therapeutics in the second quarter valued at approximately $300,000. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on LENZ. William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Finally, Raymond James assumed coverage on shares of LENZ Therapeutics in a report on Friday, September 27th. They set an “outperform” rating and a $37.00 target price on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $35.40.

LENZ Therapeutics Stock Up 0.6 %

LENZ Therapeutics stock opened at $30.97 on Friday. The firm’s 50 day simple moving average is $31.07 and its 200 day simple moving average is $24.44. LENZ Therapeutics, Inc. has a 1-year low of $14.42 and a 1-year high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.09. During the same quarter in the prior year, the business posted ($1.33) earnings per share. As a group, analysts predict that LENZ Therapeutics, Inc. will post -2.09 earnings per share for the current year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.